4 Stocks to Watch on Friday: BMY, MMM and More
Freeport-McMoRan, Pfizer, Danaher And An Industrial Stock: CNBC's 'Final Trades'
Today's Morning Movers and Top Ratings: AAPL, MMM, NVDA, COIN and More
Dividend Roundup: Wells Fargo, General Motors, Merck, Delta Air Lines, and More
Bristol-Myers Gains After Q2 Beat and Late-stage Trial Win
US Stocks Look To End Week On High Note As Nvidia Leads Mega-Caps Higher In Premarket Ahead Of Key Inflation Data
Bristol-Myers Squibb in Charts: Q2 Revenue From Eliquis, Opdivo Climb, While Sprycel Falls
Biogen-partnered Alzheimer's Therapy Fails to Clear EU Hurdle
S&P 500, Nasdaq Settle Lower As Tech Stocks Continue To Falter: Greed Index In 'Fear' Zone
Bristol-Myers Squibb, Deckers Outdoor And 3 Stocks To Watch Heading Into Friday
Walt Disney, Eli Lilly, AST SpaceMobile, DexCom, Tesla: Why These 5 Stocks Are On Investors' Radars Today
J&J Talc Bankruptcy Plan Appeal Denied
Novo Nordisk Shares Decline Amid Competitive Pressure
Smart Money Is Betting Big In MRK Options
Is the weight loss drug industry about to change? Viking Therapeutics rose nearly 40% intraday and hit a two-month high.
After communicating with the regulatory institution FDA, USA's Viking Therapeutics is pushing forward the weight-loss candidate drug VK2735 to phase III clinical trials ahead of schedule, potentially bringing the launch time forward by one year. This drug is expected to be injected once a month, which is more convenient than the same miraculous drug from Eli Lilly and Co and Novo Nordisk A/S. The oral version of VK2735 will start mid-term trials in the fourth quarter of this year.
Viking Therapeutics Stock Surges 31% As Company Advances Weight Loss Drug To Late-Stage Trial
What's Going On With Pfizer Stock Thursday?
AC Immune Stock Climbs 7% on FDA Fast Track Status for Alzheimer's Drug
Why Eli Lilly and Company Shares Are Moving Lower On Thursday
Pfizer Hemophilia B Gene Therapy Durveqtix Wins EC Authorization